StopDown
Acquisition · 20 July 2026Redcliffe LabsOmnichannel diagnostics platformredcliffelabs.com ↗

Redcliffe Labs acquires Megavision Diagnostics for ₹40 Cr

By · Editor ·

  • Redcliffe Labs is an omnichannel diagnostics platform offering over 3,600 tests across India
  • It has acquired Pune-based Megavision Diagnostics Centre for ₹40 Cr ($4.14 Mn), expected to close in July 2026
  • The deal follows two smaller acquisitions and a divestiture of its fertility business earlier this year

What happened

  • Redcliffe Labs is acquiring Megavision Diagnostics Centre in a ₹40 Cr deal.
  • Megavision is a Pune-based diagnostics chain founded in 1996 with two centres in Pimpri and Nigdi.
  • It offers MRI, CT scans, sonography, ECG, and mammography services.
  • Megavision's annual revenue is about ₹20 Cr.
  • The transaction is expected to close later this month (July 2026).
  • Redcliffe will retain Megavision's entire workforce.
  • Weeks before this deal, Redcliffe acquired Prime Sonography and Diagnostic Center (Kota) for about ₹5 Cr and Sarvodaya Diagnostics (Ajmer) for about ₹10 Cr.
  • Earlier in 2026, Redcliffe divested its fertility business Crysta IVF to Moon Care Pvt Ltd for about ₹100 Cr.

Why it matters

  • Redcliffe's revenue grew 12% to ₹470 Cr in FY26 from ₹418 Cr in FY25.
  • Its EBITDA loss margin narrowed to -13% in FY26 from -24% in FY25.
  • The company targets revenue of about ₹700 Cr in FY27, nearly 50% growth.
  • Redcliffe has raised $115 Mn to date from investors including LeapFrog Investments and HealthQuad.

The business

  • Redcliffe Labs is an omnichannel diagnostics platform with over 3,600 pathology tests.
  • It offers genetic and DNA-based screening for reproductive health, cancer, and wellness.
  • The company operates in 70-80 cities across India.
  • It has 80+ self-owned certified labs and 2,000+ collection centres.
  • Home sample collection accounts for nearly half of its business.
  • Redcliffe served more than 4.3 Mn customers in FY26, conducting 24 Mn diagnostic tests.
  • 64% of its customer base comes from Tier I and II cities.
  • It provides AI-enabled diagnostic reports, consultations, and diet plans through its mobile app.

The founders

Aditya Kandoi

Cofounder and CEO
in
  • Cofounder and CEO of Redcliffe Labs.

Dheeraj Jain

Cofounder and Chairman
  • Cofounder and Chairman of Redcliffe Labs.

In numbers

₹40 CrDeal value · 2026
₹20 CrMegavision annual revenue
₹470 CrRedcliffe revenue · FY26
₹418 CrRedcliffe revenue · FY25
-13%Redcliffe EBITDA loss margin · FY26
-24%Redcliffe EBITDA loss margin · FY25
-80%Redcliffe EBITDA loss margin · FY23
40%Redcliffe CAGR
₹700 CrRedcliffe revenue target · FY27
4.3 MnCustomers served · FY26
24 MnDiagnostic tests conducted · FY26
$115 MnTotal funding raised

What happens next

  • Redcliffe targets revenue of about ₹700 Cr in FY27, nearly 50% year-on-year growth.

Up against

HealthiansThyrocareDr Lal PathLabsSRL DiagnosticsApollo Diagnostics

Words to know

EBITDA
Earnings Before Interest, Taxes, Depreciation, and Amortisation – a measure of a company's operating profitability.
Omnichannel
A business model that integrates online and offline channels to provide a seamless customer experience.
Phlebotomist
A trained professional who draws blood from patients for medical testing.

The numbers around it

Redcliffe Labs has 4 funding rounds in StopDown's archive, $115 Mn raised in all.

#The numbers around it
WhenRoundAmountLed by
17 September 2024Series C$42MIFU (Denmark's Investment Fund for Developing Countries)
13 August 2023growth$80 million
29 September 2022Series B$100-125 million
6 May 2022Series B$61MLeapFrog Investments

Healthcare & Life Sciences in July 2026: 11 rounds with a disclosed amount, $87.1 million in all; the biggest was Iswarya (Rs 350 crore). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Mergers and acquisitions: An acquisition is when one company buys another, and a merger is when two companies combine into one. For most Indian startups a sale is a likelier exit than an IPO, and the Competition Commission of India (CCI) must approve deals that cross its asset, turnover or ₹2,000 crore deal-value limits.

Everything on Redcliffe Labs → · All startup news on 20 July 2026 →

Is this Redcliffe Labs? Get your “Featured on StopDown” badge →